PARTRUVIX Trademark

Trademark Overview

On Thursday, July 1, 2021, a trademark application was filed for PARTRUVIX with the United States Patent and Trademark Office. The USPTO has given the PARTRUVIX trademark a serial number of 90807548. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 22, 2024. This trademark is owned by BeiGene, Ltd.. The PARTRUVIX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases and infectious diseases
partruvix

General Information

Serial Number90807548
Word MarkPARTRUVIX
Filing DateThursday, July 1, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 22, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 26, 2022

Trademark Statements

Goods and ServicesPharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases and infectious diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, September 13, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBeiGene, Ltd.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressSan Mateo, CA 94404
Party NameBeiGene, Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGrand Cayman KY1-1108
KY

Trademark Events

Event DateEvent Description
Tuesday, March 22, 2022ASSIGNED TO EXAMINER
Thursday, March 24, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 5, 2021NEW APPLICATION ENTERED
Monday, September 13, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, April 26, 2022PUBLISHED FOR OPPOSITION
Wednesday, April 6, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 26, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 21, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, December 8, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, December 8, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, December 8, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, December 8, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, November 2, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, November 2, 2022SOU EXTENSION 1 FILED
Wednesday, November 2, 2022SOU EXTENSION 1 GRANTED
Friday, November 4, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 8, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, May 8, 2023SOU TEAS EXTENSION RECEIVED
Friday, November 3, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 22, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, July 22, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Wednesday, November 1, 2023SOU EXTENSION 3 GRANTED
Monday, May 8, 2023SOU EXTENSION 2 FILED
Monday, May 8, 2023SOU EXTENSION 2 GRANTED
Wednesday, May 10, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 1, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, November 1, 2023SOU EXTENSION 3 FILED

Related Keywords

partruvix diseases infectious inflammatory autoimmune treatment cancer pharmaceuticals